Showing all entries tagged with »rare diseases«
February 22, 2023
There is still a way to go to tackle the 95% of rare diseases without treatments and Rare Disease Day 2023 serves as an important reminder of the arduous tasks ahead required to design a brighter future for European people… read more
October 12, 2022
The EU biopharmaceutical ecosystem is currently languishing in third place globally. EUCOPE’s Alexander Natz discusses how the European Commission’s most fundamental review of the pharmaceutical legislation in decades is supposed to change that but in reality, is discouraging innovation and competitiveness…. read more
April 27, 2022
With the European Union’s new Regulation (EU) 2021/2282 on health technology assessment, the evaluation of certain new therapies will now be performed jointly at the European level for the first time. The aims are to speed up access to new… read more
February 26, 2021
On 27 January, the European Commission launched the consultation on the European Health Emergency Preparedness and Response Authority, HERA for short. The consultation, which main aim is to issue a legislative proposal on the new authority by the end of… read more
May 15, 2020
The 10th European Conference on Rare Diseases (ECRD), the largest patient-led event on rare diseases and orphan products, presented an excellent opportunity for exchange among the patient community and experts from various backgrounds. Bringing the perspective of OMP focused small… read more
You are currently viewing a placeholder content from Facebook. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Instagram. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from X. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More Information